Using MIPs for medicine

– Imprinting a difference – for patients

Welcome to MipSalus

MipSalus is dedicated to developing new, non-systemic pharmaceutical drugs for treatment of metabolic orphan diseases

New proprietary drug

MipSalus is developing a new proprietary drug – the first in a new class of medicines – for the treatment of all variants of HPA (Hyperphenylalaninemia)

LEARN MORE

The disease

Phenylketonuria (PKU) is a serious, congenital, lifelong metabolic disease caused by a defect in the phenylalanine hydroxylase (PAH) enzyme.

LEARN MORE

Home sensor

MipSalus is committed to developing a home sensor allowing PKU patients to conveniently monitor the concentration of phenylalanine (Phe) in their blood.

LEARN MORE

MANAGEMENT

NICOLAS O. KROGHCEO and member of the Board

KLAUS GREGORIUSCSO and member of the Board

JENS PETER TOFTChairman of the Board

ABOUT THE COMPANY

MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. MipSalus currently focuses on developing a breakthrough treatment of the rare and potentially invalidating disease Phenylketonuria (PKU) using phenylalanine-binding MIPs to block the uptake of dietary phenylalanine.

The name MipSalus is a combination of the abbreviation MIP – Molecular Imprinted Polymers – and Salus, the ancient Roman goddess of health and prosperity.

Recently, as a spin-off of the PKU drug project and using the Phe-binding MIPs, MipSalus has initiated development of a home sensor allowing PKU patients to monitor their disease and swiftly adjust food and medication.